

High prevalence of asymptomatic vertebral fractures in chronic glucocorticoid therapy: A cross-sectional outpa

Bone

39, 253-259

DOI: [10.1016/j.bone.2006.02.005](https://doi.org/10.1016/j.bone.2006.02.005)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo. <i>Journal of Endocrinology</i> , 2007, 195, 229-240.	1.2	28
2	Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1404-1412.	1.3	30
3	Glucocorticoid-induced osteoporosis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 446-450.	1.2	35
4	An update on glucocorticoid-induced osteoporosis. <i>Current Opinion in Internal Medicine</i> , 2007, 6, 544-549.	1.5	23
5	A Qualitative Study of Menopause Among Women With Disabilities. <i>Advances in Nursing Science</i> , 2007, 30, 123-138.	0.6	10
7	Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs. <i>Bone</i> , 2007, 40, 645-655.	1.4	22
9	Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, 2379-2386.	0.9	53
10	Are bisphosphonates more effective than vitamin D3 analogs for the prevention of glucocorticoid-induced osteoporosis?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 206-207.	2.9	0
11	Alterations in Proximal Femur Geometry in Children Treated with Glucocorticoids for Crohn Disease or Nephrotic Syndrome: Impact of the Underlying Disease. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 551-559.	3.1	43
12	Glucocorticoid-induced osteoporosis: pathophysiology and therapy. <i>Osteoporosis International</i> , 2007, 18, 1319-1328.	1.3	914
13	Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. <i>Osteoporosis International</i> , 2008, 19, 357-364.	1.3	33
14	Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. <i>Osteoporosis International</i> , 2008, 19, 839-847.	1.3	30
15	Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: a prospective observational cohort study. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 499-505.	1.3	28
16	Quantitative ultrasound does not identify patients with an inflammatory disease at risk of vertebral deformities. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 72.	0.8	3
17	Diagnostic Imaging Practice Guidelines for Musculoskeletal Complaints in Adults—An Evidence-Based Approach—Part 3: Spinal Disorders. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2008, 31, 33-88.	0.4	94
18	Postmenopausal Canadian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone. <i>European Journal of Internal Medicine</i> . 2008. 19. 51-56.	1.0	14
19	Vertebral Fracture Assessment: The 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2008, 11, 92-108.	0.5	201
20	Optimum management of glucocorticoid-treated patients. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 262-271.	2.9	23

#	ARTICLE	IF	CITATIONS
21	The epidemiology of glucocorticoid-associated adverse events. <i>Current Opinion in Rheumatology</i> , 2008, 20, 131-137.	2.0	329
22	Clinical and Basic Aspects of Glucocorticoid Action in Bone. , 2008, , 955-981.		12
23	Long-term therapy in COPD: any evidence of adverse effect on bone?. <i>International Journal of COPD</i> , 2009, 4, 365.	0.9	42
24	Treatment of Polymyalgia Rheumatica. <i>Archives of Internal Medicine</i> , 2009, 169, 1839.	4.3	104
25	Glucocorticoid-induced osteoporosis: treatment update and review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009, 1, 71-85.	1.2	48
26	Adding Omalizumab to the Therapy of Adolescents With Persistent Uncontrolled Moderateâ€”Severe Allergic Asthma. <i>Clinical Pediatrics</i> , 2009, 48, 859-865.	0.4	21
27	Glucocorticoids and the risk of osteoporosis. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 33-47.	1.0	40
28	Age Dependence of Early Symptomatic Vertebral Fracture with High-Dose Glucocorticoid Treatment for Collagen Vascular Diseases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1671-1677.	1.8	39
29	Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 574-583.	1.3	22
30	Risk factors of vertebral fractures in women with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2009, 28, 579-585.	1.0	57
31	Bone health in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009, 11, 177-184.	2.1	31
32	Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study. <i>Osteoporosis International</i> , 2009, 20, 989-998.	1.3	109
33	HIGH PREVALENCE AND EARLY COMPLICATION OF SYMPTOMATIC VERTEBRAL FRACTURE IN ELDERLY PEOPLE TREATED WITH HIGHâ€”DOSE GLUCOCORTICOID. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 188-189.	1.3	6
34	Assessment of osteoporotic vertebral fractures using specialized workflow software for 6-point morphometry. <i>European Journal of Radiology</i> , 2009, 70, 142-148.	1.2	40
36	Quality of life in women with postmenopausal osteoporosis: Correlation between QUALEFFO 41 and SF-36. <i>Maturitas</i> , 2009, 62, 85-90.	1.0	52
37	Recurrent fractures in an elderly patient with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2009, 12, 256-263.	0.9	0
38	A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2009, 19, 140-146.	0.9	14
39	Incidence of Symptomatic Vertebral Fracture with Highdose Glucocorticoid Treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006. <i>Endocrine Journal</i> , 2009, 56, 591-599.	0.7	11

#	ARTICLE	IF	CITATIONS
40	Treatment of Cushing disease: overview and recent findings. Therapeutics and Clinical Risk Management, 2010, Volume 6, 505-516.	0.9	57
41	Glucocorticoid Attenuates the Anabolic Effects of Parathyroid Hormone on Fracture Repair. Calcified Tissue International, 2010, 87, 68-76.	1.5	18
42	Using clinical risk factors and bone mineral density to determine who among patients undergoing bone densitometry should have vertebral fracture assessment. Osteoporosis International, 2010, 21, 2083-2091.	1.3	19
43	Underreported vertebral fractures in an Italian population: comparison of plain radiographs vs quantitative measurements. Radiologia Medica, 2010, 115, 1101-1110.	4.7	6
44	Glucocorticoid-Induced Osteoporosis: A Review. Clinical Reviews in Bone and Mineral Metabolism, 2010, 8, 15-26.	1.3	20
45	Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid. Gender Medicine, 2010, 7, 218-229.	1.4	15
46	Meta-analysis on the Risk Factors for Fracture in Patients with Rheumatoid Arthritis. The Journal of the Korean Rheumatism Association, 2010, 17, 105.	0.1	1
47	Glucocorticoid-induced Osteoporosis. , 2010, , 415-421.		0
48	Interleukin-1 is essential for systemic inflammatory bone loss. Annals of the Rheumatic Diseases, 2010, 69, 284-290.	0.5	118
49	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Annals of the Rheumatic Diseases, 2010, 69, 1269-1274.	0.5	308
50	Bone Health in Disorders of Sex Differentiation. Sexual Development, 2010, 4, 270-284.	1.1	40
51	Genistein Aglycone Demonstrates a Protective and Reversible Effect on the Development of Steroid-Induced Secondary Osteoporosis and Increases Bone Breaking Strength in Vivo. Journal of Clinical Densitometry, 2010, 13, 111.	0.5	2
52	Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity. Bone, 2010, 46, 564-570.	1.4	114
53	Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 2010, 104, 260-266.	1.3	43
54	Drug-induced Osteoporosis: Mechanisms and Clinical Implications. American Journal of Medicine, 2010, 123, 877-884.	0.6	234
55	Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone, 2010, 46, 747-751.	1.4	97
57	Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Annals of Allergy, Asthma and Immunology, 2010, 105, 465-470.	0.5	16
58	Prevalence and risk factors of vertebral compression fractures in female SLE patients. Arthritis Research and Therapy, 2010, 12, R153.	1.6	28

#	ARTICLE	IF	CITATIONS
59	Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 778-784.	0.5	61
60	Update on Glucocorticoid-Induced Osteoporosis. <i>Rheumatic Disease Clinics of North America</i> , 2011, 37, 415-431.	0.8	33
61	Glucocorticoid-Induced Bone Disease. <i>New England Journal of Medicine</i> , 2011, 365, 62-70.	13.9	575
62	Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. <i>Bone</i> , 2011, 48, 1221-1231.	1.4	50
63	Osteoporosis inducida por corticoides. <i>EMC - Aparato Locomotor</i> , 2011, 44, 1-11.	0.1	0
64	Bone Health in Patients with Multiple Sclerosis. <i>Journal of Osteoporosis</i> , 2011, 2011, 1-9.	0.1	15
65	Elevated Incidence of Fractures in Solid-Organ Transplant Recipients on Glucocorticoid-Sparing Immunosuppressive Regimens. <i>Journal of Osteoporosis</i> , 2011, 2011, 1-8.	0.1	28
67	Age, Initial Dose and Dose Increase are Independent Risk Factors for Symptomatic Vertebral Fractures in Glucocorticoid-Treated Male Patients. <i>Internal Medicine</i> , 2011, 50, 817-824.	0.3	14
69	<i>In Vitro</i> and <i>In Vivo</i> Inhibition of Glucocorticoid-Induced Osteoporosis by the Hexane Extract of <i>Poncirus trifoliata</i> . <i>Phytotherapy Research</i> , 2011, 25, 1000-1010.	2.8	21
70	Disease-related Risk of Vertebral Fracture During Glucocorticoid Treatment of Collagen Vascular Diseases. <i>Journal of Rheumatology</i> , 2011, 38, 2270-2272.	1.0	3
71	Prevention of glucocorticoid-induced osteoporosis: a re-audit of dual-energy x-ray absorptiometry scan access and management guideline compliance. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 251-255.	0.3	1
72	Osteoporosis en enfermedades reumáticas. <i>Revista Médica Clínica Las Condes</i> , 2012, 23, 425-431.	0.2	0
73	Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 580-593.	0.8	66
74	Steroid-induced osteoporosis. <i>Aging Health</i> , 2012, 8, 471-477.	0.3	2
75	Mechanisms of bone fragility in a mouse model of glucocorticoid-treated rheumatoid arthritis: Implications for insufficiency fracture risk. <i>Arthritis and Rheumatism</i> , 2012, 64, 3649-3659.	6.7	39
76	Antiresorptive therapies for osteoporosis: a clinical overview. <i>Nature Reviews Endocrinology</i> , 2012, 8, 81-91.	4.3	164
78	Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. <i>Bone</i> , 2012, 50, 289-295.	1.4	55
79	Glucocorticoid-Induced Osteoporosis and Osteonecrosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 595-611.	1.2	299

#	ARTICLE	IF	CITATIONS
80	Prevalence of vertebral fractures and quality of life in a sample of postmenopausal Brazilian women with osteoporosis. <i>Archives of Osteoporosis</i> , 2012, 7, 101-106.	1.0	14
81	Mechanism of Glucocorticoid-Induced Osteoporosis: An Update. , 0, , .		6
82	High prevalence of radiological vertebral fractures in HIV-infected males. <i>Endocrine</i> , 2012, 41, 512-517.	1.1	52
83	Glucocorticoid-Induced Osteoporosis. , 2013, , 1191-1223.		5
84	Bone mineral density and vitamin D levels in erythropoietic protoporphyria. <i>Endocrine</i> , 2013, 44, 803-807.	1.1	13
85	Bronchopneumopathie obstructive, asthme et pathologie osseuse (dont corticostéroïdes inhalés). <i>Revue Du Rhumatisme Monographies</i> , 2013, 80, 136-140.	0.0	0
87	Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1355-1368.	3.1	147
88	Validation of the Portuguese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-41) in Brazilian women with postmenopausal osteoporosis with vertebral fracture. <i>Clinical Rheumatology</i> , 2013, 32, 1585-1592.	1.0	9
89	The frequency of osteoporosis in patients with pemphigus vulgaris on treatment. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2013, 79, 211.	0.2	9
90	Management issues with exogenous steroid therapy. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 612.	0.2	21
91	Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. <i>Rheumatology</i> , 2013, 52, 1058-1069.	0.9	15
92	Prevalence and risk factors of vertebral fracture in female Japanese patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2013, 23, 765-773.	0.9	14
93	Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population. <i>Gynecological Endocrinology</i> , 2013, 29, 678-682.	0.7	7
94	Osteoporosis and rheumatic diseases. <i>Reumatismo</i> , 2014, 66, 125-135.	0.4	55
95	The Influence of Vertebral Fracture on the Functional Disability of Patients with Rheumatoid Arthritis. <i>Journal of Korean Medical Science</i> , 2014, 29, 859.	1.1	5
96	Glucocorticoid-induced osteoporosis: an overview. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 311-326.	0.3	8
97	Short-term glucocorticoid treatment causes spinal osteoporosis in ovariectomized rats. <i>European Spine Journal</i> , 2014, 23, 2437-2448.	1.0	16
98	Bone Geometry, Volumetric Bone Mineral Density, Microarchitecture and Estimated Bone Strength in Caucasian Females with Systemic Lupus Erythematosus. A Cross-Sectional Study Using HR-pQCT. <i>Calcified Tissue International</i> , 2014, 95, 530-539.	1.5	9

#	ARTICLE	IF	CITATIONS
99	Comparison of radiological and clinical results of balloon kyphoplasty according to anterior height loss in the osteoporotic vertebral fracture. <i>Spine Journal</i> , 2014, 14, 2281-2289.	0.6	37
100	Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients. <i>Journal of Bone and Mineral Metabolism</i> , 2014, 32, 725-731.	1.3	17
101	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. <i>Osteoporosis International</i> , 2014, 25, 441-446.	1.3	49
102	2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Joint Bone Spine</i> , 2014, 81, 493-501.	0.8	92
103	Protective effects of necrostatin-1 on glucocorticoid-induced osteoporosis in rats. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 144, 455-462.	1.2	34
104	Actualisation 2014 des recommandations sur la prÃ©vention et le traitement de lâ€™ostÃ©oporse cortico-induite. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 385-394.	0.0	8
105	Secondary osteoporosis: Pathophysiology & diagnosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 911-935.	2.2	50
106	Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. <i>Osteoporosis International</i> , 2014, 25, 2263-2269.	1.3	17
107	Parathyroid hormone pulsatility: physiological and clinical aspects. <i>Bone Research</i> , 2015, 3, 14049.	5.4	40
108	Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 300.	0.8	32
109	Decisional support to prevent adverse drug reactions of long latency: pilot randomized controlled intervention for glucocorticoid-induced diabetes. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 614-619.	0.9	4
110	Assessment and management of glucocorticoid-induced osteoporosis. <i>The Prescriber</i> , 2015, 26, 31-35.	0.1	11
111	Incidence of Symptomatic Vertebral Fractures Among Newly Diagnosed Autoimmune Diseases Initiating Glucocorticoid Therapy. <i>Medicine (United States)</i> , 2015, 94, e875.	0.4	3
112	Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. <i>Osteoporosis International</i> , 2015, 26, 961-968.	1.3	42
113	Glucocorticoid-induced osteoporosis. <i>RMD Open</i> , 2015, 1, e000014-e000014.	1.8	223
114	Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial. <i>Bone</i> , 2015, 75, 222-228.	1.4	71
115	Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: Results from a large prospective observational cohort study. <i>Modern Rheumatology</i> , 2015, 25, 373-378.	0.9	27
116	MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management. <i>European Journal of Endocrinology</i> , 2015, 173, R131-R151.	1.9	215

#	ARTICLE	IF	CITATIONS
117	Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density. <i>Journal of Endocrinology</i> , 2015, 224, 97-108.	1.2	23
118	Parathyroid Hormone and Glucocorticoid-induced Osteoporosis. , 2015, , 837-842.		0
119	Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometry. <i>HIV/AIDS - Research and Palliative Care</i> , 2016, 8, 109.	0.4	6
120	The Role of the Immune System in the Development of Osteoporosis and Fracture Risk. , 2016, , 187-214.		2
121	Idiopathic pulmonary fibrosis a rare disease with severe bone fragility. <i>Internal and Emergency Medicine</i> , 2016, 11, 1087-1094.	1.0	13
122	Curcumin alleviates glucocorticoid-induced osteoporosis by protecting osteoblasts from apoptosis <i>in vivo</i> and <i>in vitro</i> . <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 268-276.	0.9	47
123	Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. <i>Arthritis and Rheumatology</i> , 2016, 68, 2122-2128.	2.9	76
125	Skeletal Fragility in Endogenous Hypercortisolism. <i>Frontiers of Hormone Research</i> , 2016, 46, 66-73.	1.0	21
126	Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. <i>Osteoporosis International</i> , 2016, 27, 3239-3249.	1.3	75
127	A review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis population. <i>Bone</i> , 2016, 90, 107-115.	1.4	12
128	High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. <i>Bone</i> , 2016, 84, 88-92.	1.4	41
129	Association between trabecular bone score and risk factors for fractures in Korean female patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 540-545.	0.9	25
130	Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. <i>Osteoporosis International</i> , 2016, 27, 1709-1718.	1.3	106
131	Management of severe osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 473-488.	0.9	107
132	Epidemiology of Vertebral Fractures. <i>Journal of Clinical Densitometry</i> , 2016, 19, 8-22.	0.5	271
133	The Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse Model. <i>Pharmaceutical Research</i> , 2016, 33, 186-193.	1.7	37
134	Osteoporotic Vertebral Fractures as Part of Systemic Disease. <i>Journal of Clinical Densitometry</i> , 2016, 19, 70-80.	0.5	7
135	Bone status in glucocorticoid-treated men and women. <i>Osteoporosis International</i> , 2016, 27, 39-48.	1.3	61

#	ARTICLE	IF	CITATIONS
136	Correlations Between Sagittal Spinal Balance and Quality of Life in Rheumatoid Arthritis. <i>Clinical Spine Surgery</i> , 2017, 30, E412-E417.	0.7	14
137	Incidence of Vertebral Fractures in Women with Systemic Lupus Erythematosus After 8 Years of Follow-Up. <i>Calcified Tissue International</i> , 2017, 101, 291-299.	1.5	10
138	Corticosteroid treatment exacerbates bone osteopenia in mice with gonadal hormone deficiency-induced osteoporosis. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 105, 41-46.	1.9	9
139	2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Arthritis Care and Research</i> , 2017, 69, 1095-1110.	1.5	303
140	2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1521-1537.	2.9	399
141	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1-9.	0.6	126
142	Descripci3n de los factores de riesgo biol3gicos para pseudoartrosis. <i>Repertorio De Medicina Y Cirugia</i> , 2017, 26, 172-177.	0.0	1
143	Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. <i>Journal of Orthopaedics and Traumatology</i> , 2017, 18, 3-36.	1.0	133
144	Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid. <i>Medicine (United States)</i> , 2017, 96, e5959.	0.4	13
145	Glucocorticoid: A potential role in microgravity-induced bone loss. <i>Acta Astronautica</i> , 2017, 140, 206-212.	1.7	8
146	Autoimmune arthritis deteriorates bone quantity and quality of periarticular bone in a mouse model of rheumatoid arthritis. <i>Osteoporosis International</i> , 2017, 28, 709-718.	1.3	9
147	A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis. <i>Calcified Tissue International</i> , 2017, 100, 67-79.	1.5	15
148	Acromegalic osteopathy. <i>Pituitary</i> , 2017, 20, 63-69.	1.6	38
150	Use of corticosteroids is not associated with repeated vertebroplasty or kyphoplasty within one year after the surgery in patient older than 50 years. <i>Acta Orthopaedica Et Traumatologica Turcica</i> , 2017, 51, 459-465.	0.3	0
151	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced Osteoporosis Tool (GIOTTO) study. <i>Reumatismo</i> , 2017, 69, 30.	0.4	36
153	High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 956-964.	1.8	39
154	Multiple vertebral fractures associated with glucocorticoid-induced osteoporosis treated with teriparatide followed by kyphosis correction fusion: a case report. <i>Osteoporosis International</i> , 2018, 29, 1211-1215.	1.3	2
155	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 445-454.	5.5	148

#	ARTICLE	IF	CITATIONS
156	Bone mineral density is compromised in very long-term survivors of irradiated childhood brain tumor. <i>Acta Oncologica</i> , 2018, 57, 665-674.	0.8	18
157	Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment. <i>Clinical Endocrinology</i> , 2018, 88, 380-387.	1.2	5
158	Bone safety of dual-release hydrocortisone in patients with hypopituitarism. <i>Endocrine</i> , 2018, 60, 528-531.	1.1	29
159	Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency. <i>Endocrine Connections</i> , 2018, 7, 811-818.	0.8	29
160	Vitamin D and Glucocorticoid-Induced Osteoporosis. <i>Frontiers of Hormone Research</i> , 2018, , 149-160.	1.0	7
161	Insufficiency fracture of the distal radius after Sauvage-Kapandji procedure in a rheumatoid arthritis patient: a case report and literature review. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 121-124.	0.3	1
162	Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 612-620.	1.0	20
163	Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 263.	0.4	6
164	Effects of alendronate for treatment of glucocorticoid-induced osteoporosis. <i>Medicine (United States)</i> , 2018, 97, 1000000.	0.4	22
165	Management of difficult osteoporosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 835-847.	1.4	11
166	Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. <i>Journal of Bone Metabolism</i> , 2018, 25, 195.	0.5	33
167	Comorbidities in rheumatic arthritis. <i>Reumatologia</i> , 2018, 56, 228-233.	0.5	29
168	Bone Mass, Microstructure, and Strength Can Discriminate Vertebral Fracture in Patients on Long-Term Steroid Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3340-3349.	1.8	10
169	The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study. <i>Bone</i> , 2018, 117, 83-90.	1.4	15
170	Pituitary Diseases and Bone. <i>Endocrine Reviews</i> , 2018, 39, 440-488.	8.9	107
171	Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study. <i>Lupus</i> , 2018, 27, 1636-1643.	0.8	2
172	WNT16 overexpression partly protects against glucocorticoid-induced bone loss. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E597-E604.	1.8	19
173	Glucocorticoid-Induced Osteoporosis: Update on Management. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 279-287.	0.6	1

#	ARTICLE	IF	CITATIONS
174	Proficiencies of Zingiber officinale against spine curve and vertebral damage induced by corticosteroid therapy associated with gonadal hormone deficiency in a rat model of osteoporosis. Biomedicine and Pharmacotherapy, 2018, 103, 1429-1435.	2.5	8
175	Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Medicine, 2018, 16, 4.	2.3	46
176	Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo. Scientific Reports, 2018, 8, 8711.	1.6	33
177	Secondary Osteoporosis. , 2019, , 253-269.		2
178	Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. , 2015, 19, 48-79.		232
179	Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis. Arthritis Research and Therapy, 2019, 21, 182.	1.6	21
180	11 β -HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy. Arthritis Research and Therapy, 2019, 21, 188.	1.6	24
181	From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2239-2252.	1.3	10
182	Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormone α 1-induced osteoclastogenesis. FASEB Journal, 2019, 33, 14394-14409.	0.2	11
183	Risk of vertebral fractures in hypoparathyroidism. Reviews in Endocrine and Metabolic Disorders, 2019, 20, 295-302.	2.6	21
184	Histomorphology. , 2019, , 91-167.		12
185	Glucocorticoid induced osteoporosis. Expert Review of Endocrinology and Metabolism, 2019, 14, 259-266.	1.2	19
186	Thy α 1: more than a marker for mesenchymal stromal cells. FASEB Journal, 2019, 33, 6689-6696.	0.2	41
188	French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Joint Bone Spine, 2019, 86, 21-28.	0.8	28
189	Capture the vertebral fracture: Risk factors as a prediction. Journal of Back and Musculoskeletal Rehabilitation, 2019, 32, 269-276.	0.4	12
190	Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves α 1 orbitopathy: a small prospective pilot study. Journal of Endocrinological Investigation, 2019, 42, 859-865.	1.8	9
191	Recommandations fran α aises de strat α gies th α rapeutiques pour la pr α vention et le traitement de l α ost α oporose induite par la castration dans le cancer de la prostate. Revue Du Rhumatisme (Edition) Tj ETQq0.0 0 rgBT2/Overlock	0.0	0
192	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology, 2020, 59, 1574-1580.	0.9	47

#	ARTICLE	IF	CITATIONS
193	Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. <i>Respiratory Research</i> , 2020, 21, 263.	1.4	1
194	The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy. <i>BMC Endocrine Disorders</i> , 2020, 20, 154.	0.9	3
195	Association between statin use and osteoporotic fracture in patients with chronic obstructive pulmonary disease: a population-based, matched case-control study. <i>Lipids in Health and Disease</i> , 2020, 19, 232.	1.2	1
196	What Role Does Trabecular Bone Score Play in Chronic Inflammatory Rheumatic Diseases?. <i>Frontiers in Medicine</i> , 2020, 7, 600697.	1.2	13
197	Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway. <i>Archives of Osteoporosis</i> , 2020, 15, 121.	1.0	2
198	Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis. <i>Journal of Orthopaedic Surgery and Research</i> , 2020, 15, 290.	0.9	7
199	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355.	1.8	5
200	Risk of fracture according to glucocorticoid use after renal biopsy: a nationwide population-based study. <i>Scientific Reports</i> , 2020, 10, 13846.	1.6	8
201	Hyperprolactinemia and bone. <i>Pituitary</i> , 2020, 23, 314-321.	1.6	24
202	Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. <i>Bone Reports</i> , 2020, 13, 100293.	0.2	15
203	Glucocorticoids Disrupt Skeletal Angiogenesis Through Transrepression of NF- κ B-Mediated Preosteoclast <i>Transcription</i> in Young Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1188-1202.	3.1	20
204	Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. <i>Rheumatology</i> , 2021, 60, 649-657.	0.9	15
205	Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e602-e614.	1.8	66
206	Bone Strength/Bone Mass Discrepancy in Glucocorticoid-Treated Adult Mice. <i>JBMR Plus</i> , 2021, 5, e10443.	1.3	7
207	Efficacy and safety of sodium Risedronate for glucocorticoid-induced Osteoporosis with rheumatoid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2021, 31, 593-599.	0.9	8
208	Glucocorticoid-induced osteoporosis and Cushing's syndrome. , 2021, , 1103-1138.		0
209	Osteoporose – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. <i>The Springer Reference Pflege, Gesundheit</i> , 2021, , 819-830.	0.2	0
210	Therapies for Preventing Bone Loss with Glucocorticoid Treatment. <i>Current Osteoporosis Reports</i> , 2021, 19, 34-39.	1.5	3

#	ARTICLE	IF	CITATIONS
211	Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020). Archives of Osteoporosis, 2021, 16, 49.	1.0	16
212	Osteopathy in mild adrenal Cushing's syndrome and Cushing disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101515.	2.2	17
213	Đ“Đ,ĐzĐ³⁄⁴Đ²Đ,Ñ,Đ°Đ¹⁄⁴Đ,Đ¹⁄²Đ³⁄⁴Đ·Ñ<Ñf Đ²Đ³⁄⁴ĐµĐ¹⁄²Đ¹⁄²Đ³⁄⁴ÑĐ»ÑfĐ¹Đ°Ñ%Đ,Ñ.... Society and Innovations, 2021, 2, 90-99.		
214	Effects of Medical Treatment of Prostate Cancer on Bone Health. Trends in Endocrinology and Metabolism, 2021, 32, 135-158.	3.1	21
215	FRAX scores are increased in patients with ANCA-associated vasculitis. International Urology and Nephrology, 2021, 53, 2333-2339.	0.6	1
216	Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. Bone, 2021, 146, 115902.	1.4	11
217	Bone mineral density at extremely low weight in patients with anorexia nervosa. Clinical Endocrinology, 2021, 95, 423-429.	1.2	2
218	Bone remodeling stages under physiological conditions and glucocorticoid in excess: Focus on cellular and molecular mechanisms. Regulatory Mechanisms in Biosystems, 2021, 12, 212-227.	0.5	1
219	Update on Glucocorticoid Induced Osteoporosis. Endocrinology and Metabolism, 2021, 36, 536-543.	1.3	9
220	Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid. International Journal of Rheumatic Diseases, 2021, 24, 1053-1060.	0.9	8
221	A novel vertebroplasty technique using a larger-diameter needle for thoracolumbar osteoporotic vertebral compression fracture. Medicine (United States), 2021, 100, e26174.	0.4	1
222	Understanding and Managing Corticosteroid-Induced Osteoporosis. Open Access Rheumatology: Research and Reviews, 2021, Volume 13, 177-190.	0.8	24
223	Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis. Archives of Osteoporosis, 2021, 16, 108.	1.0	0
225	Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease. Clinical and Experimental Nephrology, 2022, 26, 29-35.	0.7	0
226	Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe. Frontiers in Endocrinology, 2021, 12, 733611.	1.5	11
227	Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment. Frontiers in Endocrinology, 2021, 12, 753185.	1.5	6
228	Loss of glucocorticoid rhythm induces an osteoporotic phenotype in female mice. Aging Cell, 2021, 20, e13474.	3.0	9
229	Factores asociados con fracturas vertebrales asintomáticas en pacientes con artritis reumatoide en un servicio de reumatología de Bogotá (Colombia). Revista Colombiana De Reumatología, 2021, , .	0.0	0

#	ARTICLE	IF	CITATIONS
230	Secondary Osteoporosis. <i>Endocrine Reviews</i> , 2022, 43, 240-313.	8.9	85
231	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	2.6	782
232	Chapter 58. Glucocorticoid-Induced Osteoporosis. , 0, , 267-272.		7
234	A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2009, 19, 140-146.	0.9	11
235	Prevalence and risk factors of vertebral fracture in female Japanese patients with systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2013, 23, 765-773.	0.9	10
236	Glucocorticoid-Induced Osteoporosis. , 2008, , 1135-1166.		9
237	Treatment options for glucocorticoid-induced osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 721-732.	0.9	25
238	The Clinical Characteristics of Lower Lumbar Osteoporotic Compression Fractures Treated by Percutaneous Vertebroplasty : A Comparative Analysis of 120 Cases. <i>Korean Journal of Spine</i> , 2013, 10, 221.	0.9	7
239	Treatment for rheumatic polymyalgia. <i>Sovremennaya Revmatologiya</i> , 2013, .	0.1	1
240	Inhaled Corticosteroids and Bone Health. <i>Open Respiratory Medicine Journal</i> , 2015, 8, 85-92.	1.3	35
241	Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 92-6.	1.8	4
242	Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study. <i>Endocrinology and Metabolism</i> , 2020, 35, 562-570.	1.3	8
243	Therapeutic Dimensions of Bisphosphonates: A Clinical Update. <i>International Journal of Preventive Medicine</i> , 2020, 11, 166.	0.2	9
244	Prevalence and Risk Factors for Non-Vertebral Fractures in Patients Receiving Oral Glucocorticoids. <i>International Journal of Endocrinology and Metabolism</i> , 2012, 10, 480-485.	0.3	2
245	German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 49-63.	0.5	8
247	Women and Asthma. , 2010, , 245-262.		0
248	ĐjÑ,ĐμÑ€Đ³⁄₄Đ,Đ Đ³⁄₄Đ-Đ°Đ²Đ,ÑĐ,Đ¹⁄₄Đ°Ñ•Đ±Ñ€Đ³⁄₄Đ¹⁄₂Ñ...Đ,Đ°Đ»Ñ€Đ¹⁄₂Đ°Ñ•Đ°ÑÑ,Đ¹⁄₄Đ°: Ñ€ĐμĐ°Đ³⁄₄Đ¹⁄₄ĐμĐ³⁄₂Đ Đ°Ñ†Đ,Đ,Đ;Đ³⁄₄		
249	13 Systemische Osteopathien. , 2011, , 253-280.		0

#	ARTICLE	IF	CITATIONS
250	Artrite reumatoide: por que tratar apenas a artrite, sabendo que comorbidades são comuns e determinam morbidade e mortalidade?. Revista Brasileira De Reumatologia, 2012, 52, 472-473.	0.8	0
251	Hygienic habits are a risk factor for adult-onset asthma. F1000Research, 0, 2, 80.	0.8	0
252	Treatment and Prevention of Glucocorticoid-Induced Osteoporosis. , 2015, , 593-603.		0
253	Moderate Physical Activity Improves Rat Bone Ultrastructure in Experimental Osteoporosis. Acta Endocrinologica, 2016, 12, 392-400.	0.1	0
254	Risk factors for irreversible organ damages in peri- and postmenopausal women with systemic lupus erythematosus. Sovremennaya Revmatologiya, 2018, 12, 89-94.	0.1	0
258	Osteoporose – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. The Springer Reference Pflege, 2020, , 1-12.	0.2	0
259	Why Do We Need Proactive Management for Fracture Prevention in Long-Term Glucocorticoid Users?. Endocrinology and Metabolism, 2020, 35, 549-551.	1.3	0
260	Tanshinone IIA blocks dexamethasone-induced apoptosis in osteoblasts through inhibiting Nox4-derived ROS production. International Journal of Clinical and Experimental Pathology, 2015, 8, 13695-706.	0.5	18
261	Expression of HCA2 Receptors in Femoral Epiphysis and Metaphysis of Rats with Dexamethasone-Induced Osteoporosis. International Journal of Molecular and Cellular Medicine, 2016, 5, 106-13.	1.1	1
262	Glucocorticoid-induced osteoporosis and parathyroid hormone. Journal of Endocrinological Investigation, 2010, 33, 16-21.	1.8	7
263	Glucocorticoid-Induced Osteoporosis. , 2022, , 787-796.		1
269	Bone health and glucocorticoid-containing lymphoma therapy – a review of risk factors and preventative measures. British Journal of Haematology, 2022, 198, 431-442.	1.2	6
270	When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis. Frontiers in Endocrinology, 2021, 12, 782118.	1.5	14
271	High Prevalence of Vertebral Fractures Associated With Preoperative GH Levels in Patients With Recent Diagnosis of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2843-e2850.	1.8	16
272	Histological and histomorphometric aspects of continual intermittent parathyroid hormone administration on osseointegration in osteoporosis rabbit model. PLoS ONE, 2022, 17, e0269040.	1.1	1
273	11 β -Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation. International Journal of Molecular Sciences, 2022, 23, 7334.	1.8	2
274	Novel approaches to bone comorbidity in Cushing's disease: an update. Pituitary, 2022, 25, 754-759.	1.6	7
276	Prevention of Adverse Outcomes and Treatment Side Effects in Patients with Neuromuscular Disorders. Seminars in Neurology, 0, , .	0.5	0

#	ARTICLE	IF	CITATIONS
277	ACR Appropriateness Criteria® Osteoporosis and Bone Mineral Density: 2022 Update. Journal of the American College of Radiology, 2022, 19, S417-S432.	0.9	11
278	Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids. Journal of Bone and Mineral Metabolism, 0, , .	1.3	0
279	Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?. SN Comprehensive Clinical Medicine, 2023, 5, .	0.3	0
280	Factors associated with asymptomatic vertebral fractures in patients with rheumatoid arthritis in a rheumatology service in Bogotá (Colombia). Revista Colombiana De Reumatología (English Edition), 2022, 29, 274-282.	0.1	0
281	Exercise effects on glucocorticoid-induced bone loss in adults: a systematic review and meta-analysis. Rheumatology Advances in Practice, 2022, 7, .	0.3	0